Preparation and in vitro evaluation of carrier erythrocytes for RES-targeted delivery of interferon-alpha 2b.

Carrier erythrocytes is one of the most promising systemic drug delivery systems investigated in recent decades. In this study, human erythrocytes have been loaded with interferon-alpha 2b (IFN) with the aim to benefit the reticuloendothelial system (RES) targeting potential of the carrier cells. Hypotonic preswelling method was used for drug loading in erythrocytes and the entire loading procedure was evaluated and validated. The loaded amount, entrapment efficiency and cell recovery of the loading procedure were 2906.33+/-588.35IU/0.1ml, 14.53+/-2.94%, and 83.61+/-0.49%, respectively, all being practically feasible. The carrier erythrocytes were characterized in vitro in terms of their drug release kinetics, hematological indices, particle size distribution, SEM analysis, and osmotic and turbulence fragility. IFN release from carrier cells was a relatively rapid process in comparison to the cell lysis kinetics, which is unusual considering the whole body of data published on this delivery system and other protein drugs, so far. All the tested in vitro characteristics showed significant, sometimes notable changes upon drug loading procedure, both with and without the drug.

[1]  S. Pedder.  Pegylation of Interferon Alfa: Structural and Pharmacokinetic Properties , 2003, Seminars in liver disease.

[2]  E. Lightfoot,et al.  Asparaginase entrapped in red blood cells: action and survival. , 1976, Science.

[3]  J Bird,et al.  The encapsulation of insulin in erythrocytes , 1983, The Journal of pharmacy and pharmacology.

[4]  T. Tsong,et al.  Formation and resealing of pores of controlled sizes in human erythrocyte membrane , 1977, Nature.

[5]  H. Tajerzadeh,et al.  Evaluation of Hypotonic Preswelling Method for Encapsulation of Enalaprilat in Intact Human Erythrocytes , 2000, Drug development and industrial pharmacy.

[6]  Mehrdad Hamidi,et al.  Carrier Erythrocytes: An Overview , 2003, Drug delivery.

[7]  A. García-Sastre,et al.  VIRUSES AND THE TYPE I INTERFERON ANTIVIRAL SYSTEM: INDUCTION AND EVASION , 2002, International reviews of immunology.

[8]  N. Kadowaki,et al.  Natural Interferon α/β–Producing Cells Link Innate and Adaptive Immunity , 2000, The Journal of experimental medicine.

[9]  M. Hamidi,et al.  Preparation and in vitro characterization of carrier erythrocytes for vaccine delivery. , 2007, International journal of pharmaceutics.

[10]  K. Fujioka,et al.  Development of a new drug delivery system for protein drugs using silicone (II). , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[11]  N. Jain,et al.  Erythrocytes as carriers of metronidazole: In-vitro characterization , 1992 .

[12]  S. Updike,et al.  Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences. , 1983, The Journal of laboratory and clinical medicine.

[13]  S Gasic,et al.  In vivo clearance of antibody‐sensitized human drug carrier erythrocytes , 1986, Clinical pharmacology and therapeutics.

[14]  V. Dixit,et al.  Magnetically Guided Rat Erythrocytes Bearing Isoniazid: Preparation, Characterization, and Evaluation , 1997 .

[15]  F. Belardelli,et al.  Endogenous type I interferons as a defense against tumors. , 2002, Cytokine & growth factor reviews.

[16]  M. Alonso,et al.  Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  Erwin K. Kastrup,et al.  Drug facts and comparisons , 1977 .

[18]  M. Pinilla,et al.  Mouse erythrocytes as carriers for coencapsulated alcohol and aldehyde dehydrogenase obtained by electroporation in vivo survival rate in circulation, organ distribution and ethanol degradation. , 2001, Life sciences.

[19]  S. Mahor,et al.  Pegylated Protein Encapsulated Multivesicular Liposomes: A Novel Approach for Sustained Release of Interferon α , 2006, Drug development and industrial pharmacy.

[20]  John M. Kirkwood,et al.  Cancer immunotherapy: The interferon-α experience , 2002 .

[21]  C. Kim,et al.  Prolonged Blood Circulation of Methotrexate by Modulation of Liposomal Composition , 2001, Drug delivery.

[22]  S. Baron,et al.  The interferons. Mechanisms of action and clinical applications. , 1991, JAMA.

[23]  M. Rouini,et al.  In Vitro Characterization of Human Intact Erythrocytes Loaded by Enalaprilat , 2001, Drug delivery.

[24]  M. Boroujerdi,et al.  Pharmacokinetics and Tissue Uptake of Doxorubicin Associated With Erythroctte-nembrane:erithroctte-Ghosts vs Erythrocyte-Vesicles , 1990 .

[25]  R. Baker.  Entry of Ferritin into Human Red Cells during Hypotonic Haemolysis , 1967, Nature.

[26]  M. Garin,et al.  Erythrocytes as Carriers for Recombinant Human Erythropoietin , 1996, Pharmaceutical Research.

[27]  D. Lewis,et al.  Encapsulation of drugs in intact erythrocytes: an intravenous delivery system. , 1983, Biochemical pharmacology.

[28]  R H Glew,et al.  Enzyme loading of erythrocytes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[29]  N. Jain,et al.  Erythrocytes as carriers of primaquine-preparation: characterization and evaluation , 1992 .